Literature DB >> 1376555

Post-transplant recurrent hepatitis B viral liver disease. Viral-burden, steatoviral, and fibroviral hepatitis B.

M J Phillips1, R Cameron, M A Flowers, L M Blendis, P D Greig, I Wanless, M Sherman, R Superina, B Langer, G A Levy.   

Abstract

Recurrence of hepatitis is a well-documented complication of hepatitis B liver disease, post-transplantation. It is well established also that the earliest hepatocellular change is the appearance of hepatitis B viral (HBV) markers and that the disease is rapidly progressive. In this article on 17 liver transplants in 16 HBV positive patients with long-term follow-ups (100-1234 days), the distinctive pathologic features of this disease are emphasized: the extreme viral load, the steatosis, and/or fibrosis. An attempt to quantitate the magnitude of the viral burden was made and the result was a staggering figure. In one patient, an estimated 10(18) HBV core particles were present in the liver. One of two patterns of progression were noted. In four patients in addition to the massive nuclear hepatitis B core antigen (HBcAg) and cytoplasmic hepatitis B surface antigen (HBsAg) positivity, superimposed hepatitic changes led to diffuse hepatic fibrosis (fibroviral hepatitis B); and in another six patients, extraordinary hepatocellular viral marker positivity and steatosis were the hallmarks (steatoviral hepatitis B). Steatosis is not usually considered a feature of HBV liver pathology. These results suggest that more than one type of posttransfusion recurrent hepatitis B liver disease exists pathologically.

Entities:  

Mesh:

Year:  1992        PMID: 1376555      PMCID: PMC1886548     

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  33 in total

1.  Liver transplantation for patients with hepatitis B: what have we learned from our results?

Authors:  J R Lake; T L Wright
Journal:  Hepatology       Date:  1991-04       Impact factor: 17.425

2.  Results of liver transplantation for hepatitis delta disease without immunoprophylaxis.

Authors:  S Agnes; A W Avolio; S C Magalini; G Nanni; M Foco; F Serino; G Hassan; G Marinucci; G Boldrini; M Castagneto
Journal:  Transplant Proc       Date:  1989-02       Impact factor: 1.066

3.  The significance of antibody to hepatitis C virus in patients with chronic hepatitis B.

Authors:  T L Fong; A M Di Bisceglie; J G Waggoner; S M Banks; J H Hoofnagle
Journal:  Hepatology       Date:  1991-07       Impact factor: 17.425

4.  Clinical management of immunosuppressive therapy for cyclosporine-treated recipients of cadaver kidney transplants at one to six months.

Authors:  N J Feduska; J Melzer; W J Amend; F Vincenti; S Tomlanovich; O Salvatierra
Journal:  Transplant Proc       Date:  1986-04       Impact factor: 1.066

5.  Long-term immunoprophylaxis of hepatitis B virus reinfection in recipients of human liver allografts.

Authors:  W Lauchart; R Müller; R Pichlmayr
Journal:  Transplant Proc       Date:  1987-10       Impact factor: 1.066

6.  Evolution of hepatitis B virus liver disease after hepatic replacement. Practical and theoretical considerations.

Authors:  A J Demetris; S Todo; D H Van Thiel; J J Fung; Y Iwaki; G Sysyn; W Ming; J Trager; T E Starzl
Journal:  Am J Pathol       Date:  1990-09       Impact factor: 4.307

Review 7.  Eicosanoids and the liver.

Authors:  S Sinclair; G Levy
Journal:  Ital J Gastroenterol       Date:  1990-08

8.  Differential distribution of hepatitis B surface antigen and hepatitis B core antigen in the liver of hepatitis B patients.

Authors:  M B Ray; V J Desmet; A F Bradburne; J Desmyter; J Fevery; J De Groote
Journal:  Gastroenterology       Date:  1976-09       Impact factor: 22.682

9.  Histologic studies of severe delta agent infection in Venezuelan Indians.

Authors:  H Popper; S N Thung; M A Gerber; S C Hadler; M de Monzon; A Ponzetto; E Anzola; D Rivera; A Mondolfi; A Bracho
Journal:  Hepatology       Date:  1983 Nov-Dec       Impact factor: 17.425

10.  Liver allograft. Its use in chronic active hepatitis with macronodular cirrhosis, hepatitis B surface antigen.

Authors:  J L Corman; C W Putnam; S Iwatsuki; A G Redeker; K A Porter; R L Peters; G Schröter; T E Starzl
Journal:  Arch Surg       Date:  1979-01
View more
  10 in total

1.  Hepatitis B virus subviral envelope particle morphogenesis and intracellular trafficking.

Authors:  Romuald Patient; Christophe Hourioux; Pierre-Yves Sizaret; Sylvie Trassard; Camille Sureau; Philippe Roingeard
Journal:  J Virol       Date:  2007-01-31       Impact factor: 5.103

2.  Viral and host causes of fatty liver in chronic hepatitis B.

Authors:  Emin Altlparmak; Seyfettin Koklu; Mesut Yalinkilic; Osman Yuksel; Bahattin Cicek; Ertugrul Kayacetin; Tulin Sahin
Journal:  World J Gastroenterol       Date:  2005-05-28       Impact factor: 5.742

3.  Fibrosing cholestatic hepatitis in a kidney transplant recipient with hepatitis C virus.

Authors:  Takahiro Shinzato; Taro Kubo; Toshihiro Shimizu; Koji Nanmoku; Takashi Yagisawa
Journal:  CEN Case Rep       Date:  2019-01-02

4.  The Fgl2/fibroleukin prothrombinase contributes to immunologically mediated thrombosis in experimental and human viral hepatitis.

Authors:  Philip A Marsden; Qin Ning; Laisum S Fung; Xioping Luo; Yue Chen; Michael Mendicino; Anand Ghanekar; Jeremy A Scott; Teresa Miller; Camie W Y Chan; Mathew W C Chan; Wei He; Reginald M Gorczynski; David R Grant; David A Clark; M James Phillips; Gary A Levy
Journal:  J Clin Invest       Date:  2003-07       Impact factor: 14.808

Review 5.  Controversies in patient selection for liver transplantation.

Authors:  E B Keeffe; C O Esquivel
Journal:  West J Med       Date:  1993-11

6.  Fibrosing cholestatic hepatitis: clinicopathologic spectrum, diagnosis and pathogenesis.

Authors:  Shu-Yuan Xiao; Liang Lu; Hanlin L Wang
Journal:  Int J Clin Exp Pathol       Date:  2008-01-01

Review 7.  Chronic viral hepatitis B and C: an argument against the conventional classification of chronic hepatitis.

Authors:  M Schmid; R Flury; H Bühler; J Havelka; P J Grob; P U Heitz
Journal:  Virchows Arch       Date:  1994       Impact factor: 4.064

8.  The diagnostic value of biomarkers (SteatoTest) for the prediction of liver steatosis.

Authors:  Thierry Poynard; Vlad Ratziu; Sylvie Naveau; Dominique Thabut; Frederic Charlotte; Djamila Messous; Dominique Capron; Annie Abella; Julien Massard; Yen Ngo; Mona Munteanu; Anne Mercadier; Michael Manns; Janice Albrecht
Journal:  Comp Hepatol       Date:  2005-12-23

9.  Recommendations for Hepatitis B Immunoglobulin and Antiviral Prophylaxis Against Hepatitis B Recurrence After Liver Transplantation.

Authors:  Mesut Akarsu; Soner Onem; Ilker Turan; Gupse Adali; Meral Akdogan; Murat Akyildiz; Murat Aladag; Yasemin Balaban; Nilay Danis; Murat Dayangac; Genco Gencdal; Hale Gokcan; Elif Sertesen; Merve Gurakar; Murat Harputluoglu; Gokhan Kabacam; Sedat Karademir; Murat Kiyici; Ramazan Idilman; Zeki Karasu
Journal:  Turk J Gastroenterol       Date:  2021-09       Impact factor: 1.555

Review 10.  Fibrosing cholestatic hepatitis C in post-transplant adult recipients of liver transplantation.

Authors:  Tomohide Hori; Yasuharu Onishi; Hideya Kamei; Nobuhiko Kurata; Masatoshi Ishigami; Yoji Ishizu; Yasuhiro Ogura
Journal:  Ann Gastroenterol       Date:  2016-07-08
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.